Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)

Summary

The purpose of this prospective randomized clinical trial is to compare the clinical outcomes according to the duration of aspirin and clopidogrel or prasugrel with dual anti-platelet therapy after percutaneous coronary intervention in patients with advanced chronic kidney disease using a new generation drug eluting stents.

Timeline

Start

2021-03-23

Primary completion

2027-03-13

Completion

2028-03-13

Publications

• Jin IT, Lee SH, Yun KH, Kim W, Shin S, Jang JY, Cho DK, Cha JJ, Kang TS, Lee JH, Cho YK, Heo JH, Ahn SG, Lee J, Lee YJ, Lee SJ, Hong SJ, Ahn CM, Kim BK, Ko YG, Choi D, Hong MK, Jang Y, Kim JS. Optimal antiplatelet strategy in patients with advanced chronic kidney disease undergoing drug-eluting stent implantation: Design and rationale of the randomized ADAPT-CKD trial. Am Heart J. 2026 Aug;298:107437. doi: 10.1016/j.ahj.2026.107437. Epub 2026 Apr 1.

Drugs

Indications